{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:21Z","timestamp":1761630381292},"reference-count":8,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,6,21]],"date-time":"2005-06-21T00:00:00Z","timestamp":1119312000000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2005,6]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> We carried out a prospective study of the safety and efficacy of daclizumab combined with triple immunosuppression in adult recipients of at least one HLA\u2010mismatched cadaveric renal allograft. All studied patients received the same immunosuppression: a daclizumab infusion of 1\u2003mg\/kg immediately before transplantation, and at 2, 4, 6, and 8\u2003weeks following the transplantation. Infusion of cyclosporine (CsA) (0.08\u2003mg\/kg\/h) was started at the time of the operation and continued by CsA microemulsion (CsA\u2010Neoral), 3\u2003mg\/kg twice daily on day 2, methylprednisolone, 0.4\u2003mg\/kg intravenously at operation, and mycophenolate mofetil started on day 1. The dose of CsA\u2010Neoral was adjusted to maintain target blood trough levels. Oral methylprednisolone was tapered by 4\u2003mg per week to achieve a maintenance dose of 0.08\u2003mg\/kg\/day. Fifty\u2010five patients, with a mean age of 48\u2003\u00b1\u200311\u2003years, were studied. Six of them received a second renal allograft. The mean donor age was 38\u2003\u00b1\u200314\u2003years. Mean cold ischemia time was 19.5\u2003\u00b1\u20036.5\u2003h, mean value of HLA\u2010antigen mismatches was 2.7\u2003\u00b1\u20030.9, mean latest PRA value was 3\u2003\u00b1\u20037%. Fifteen patients experienced delayed graft function. During a follow\u2010up period of 3\u2003months three acute rejection episodes occurred. One patient died because of systemic aspergillosis. After 3\u2003months mean serum creatinine was 104\u2003\u00b1 38\u2003\u00b5mol\/L. Five renal allografts failed, one of them due to rejection. Patient and graft survival was 98.2% and 90.9%, respectively. Daclizumab with this triple therapy represents safe and efficient immunosuppression strategy, demonstrated with low incidence of early acute rejection episodes and an acceptable adverse event profile in cadaveric renal allograft recipients.<\/jats:p>","DOI":"10.1111\/j.1774-9987.2005.00268.x","type":"journal-article","created":{"date-parts":[[2005,6,21]],"date-time":"2005-06-21T17:12:47Z","timestamp":1119373967000},"page":"262-264","source":"Crossref","is-referenced-by-count":7,"title":["Prevention of Early Acute Rejection With Daclizumab and Triple Immunosuppression in Cadaveric Renal Allograft Recipients"],"prefix":"10.1111","volume":"9","author":[{"given":"Aljo\u0161a","family":"Kandus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Grego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrej F","family":"Bren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199701150-00007"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2003.30109.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199901150-00019"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109150-00017"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)01529-2"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801153380304"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000140767.67868.F1"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200407271-00733"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1774-9987.2005.00268.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1774-9987.2005.00268.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:11:59Z","timestamp":1697055119000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1774-9987.2005.00268.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10.1111\/j.1774-9987.2005.00268.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1774-9987.2005.00268.x","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}